Hi. I will have you know I just finished shampooing the living room carpet.? Done is done, and I am done in. Just a little too much pushing and hauling for my taste. Even with coasters under all the legs, that furniture is heavy!??
The moral to this story? There is always tomorrow…and if tomorrow doesn’t come, a half-shampooed carpet is the least of our worries! Do as I say, not as I do, and take care of yourself.
And since I am just about totally worn out, I guess that means it is time for a page. Don’t you love I think about you when my eyes are crossing, and I can’t get out of my chair?
Medscape published an article by Laird Harrison (cool name, Mom Harrison. Good job!) It seems there have been some reactions to anti-VEGF shots. A LOT of reactions. There have been “clusters” of inflammatory responses and they have many retina specialists concerned. One retina specialist was really unnerved when he had six patients with bad responses in one day!
The problem has been significant enough they will be talking about it at the American Society of Retina Specialist upcoming meeting. Maybe they will be able to do a bit of detective work and figure out what is happening. Bad batch? Allergic reactions? I don’t know, Watson, but I would suspect the game will be afoot!
If you had a bad reaction to a shot, I would suggest you make sure your specialist passes on the information. If it were a bad batch or something similar, there may need to be a recall. Get that stuff off the shelves.
Also at the ASRS conference, they will be talking about the port delivery system for ranibizumab and the phase 3 SCORE findings. SCORE is the study that compares bevacizumab to aflibercept. So far they are finding bevacizumab to have comparable effects.
HAWK and HARRIER are not only fighter jets. They are also studies trying to find a way to predict which anti-VEGF may work for a given patient….hmm. British fighter jets. British studies? No se.
And coming to the dry side, it appears APL2 is being investigated as a prophylactic measure for dry AMD. Remember the information from the poster session suggested APL-2 slowed the progression of atrophy but did nothing for acuity. Not sure why that would happen but most people want to see acuity losses slow and people became skeptical. Not sure what this move to prevention is all about but it may bear watching.
As usual, wet AMD continues to be the favored child with the researchers. Scanning the Retina Specialist article about what is in the pipeline and expected to emerge in 2018, the great majority of potential new products are for the wet form. There were three for dry and one of these was “lamp stuff” which most of us know failed in phase 3 trials.
Frustrating as it may be, hang in there oh denizens of the dry side. Miracles have been known to happen. I shampooed my carpet!?